secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001438533-22-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA
--------------------------------------------------------------------------------

- Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).
- Net product sales $50.8M, down from $54.2M; total revenue $53.5M.
- FDA set new PDUFA date Feb 17, 2023 for sparsentan in IgAN after REMS update.
- EMA accepted CMA application for sparsentan in IgAN; decision expected H2 2023.
- Cash, equivalents & marketable securities $506.3M; DUPLEX FSGS data expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/tvtx-20221027.htm
  HTML page:      https://secwatch.observer/filing/0001438533-22-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer